Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.
*c-FOS/AP-1; *harpagoside; *IL-6; *MMP-13; *osteoarthritis; CCAAT-Enhancer-Binding Protein-beta/metabolism; Chemokines/metabolism; Chondrocytes/*drug effects/metabolism; Drug Evaluation; Glycosides/pharmacology/*therapeutic use; Harpagophytum; Humans; Interleukin-1beta; Interleukin-6/antagonists & inhibitors/*metabolism; Matrix Metalloproteinase 13/metabolism; NF-kappa B/metabolism; Osteoarthritis/*drug therapy/metabolism; Phytotherapy; Plant Extracts/pharmacology/therapeutic use; Preclinical; Primary Cell Culture; Proto-Oncogene Proteins c-fos/metabolism; Pyrans/pharmacology/*therapeutic use; Reactive Oxygen Species/metabolism; Transcription Factor AP-1/metabolism
There is growing evidence in support of the involvement of inflammatory response in the pathogenesis of osteoarthritis (OA). Harpagoside, one of the bioactive components of Harpagophytum procumbens (Hp), has been shown to possess anti-inflammatory properties. Here we used an in vitro model of inflammation in OA to investigate the potential of harpagoside to suppress the production of inflammatory cytokines/chemokines such as IL-6 and matrix degrading proteases. We further investigated the likely targets of harpagoside in primary human OA chondrocytes. OA chondrocytes were pre-treated with harpagoside before stimulation with IL-1beta. mRNA expression profile of 92 cytokines/chemokines was determined using TaqMan Human Chemokine PCR Array. Expression levels of selected mRNAs were confirmed using TaqMan assays. Protein levels of IL-6 and MMP-13 were assayed by ELISA and immunoblotting. Total protein levels and phosphorylation of signaling proteins were determined by immunoblotting. Cellular localization of
Haseeb Abdul; Ansari Mohammad Yunus; Haqqi Tariq M
Journal of orthopaedic research : official publication of the Orthopaedic Research Society
2017
2017-02
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1002/jor.23262" target="_blank" rel="noreferrer noopener">10.1002/jor.23262</a>
A wogonin-rich-fraction of Scutellaria baicalensis root extract exerts chondroprotective effects by suppressing IL-1beta-induced activation of AP-1 in human OA chondrocytes.
Cells; Chemical Fractionation/methods; Chondrocytes/*drug effects/metabolism; Cultured; Cyclooxygenase 2/genetics/metabolism; Flavanones/*pharmacology; Gene Expression Regulation/drug effects; Humans; Interleukin-1beta/pharmacology; Interleukin-6/genetics/metabolism; Osteoarthritis/pathology; Plant Extracts/*pharmacology; Plant Roots/*chemistry; Protective Agents/pharmacology; Reactive Oxygen Species/metabolism; Scutellaria baicalensis/*chemistry; Transcription Factor AP-1/genetics/*metabolism
Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation and sustained oxidative stress. The root extract of Scutellaria baicalensis (SBE) has been used for the treatment of inflammatory and other diseases. Here, we performed activity-guided HPLC-fractionation of SBE, identified the active ingredient(s) and investigated its chondroprotective potential. We found that the Wogonin containing fraction-4 (F4) was the most potent fraction based on its ability to inhibit ROS production and the suppression of catabolic markers including IL-6, COX-2, iNOS, MMP-3, MMP-9,
Khan Nazir M; Haseeb Abdul; Ansari Mohammad Y; Haqqi Tariq M
Scientific reports
2017
2017-03
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1038/srep43789" target="_blank" rel="noreferrer noopener">10.1038/srep43789</a>